The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Open accessAbstract
BACKGROUND: The purpose of this study was to determine among maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension whether in comparison with a β-blocker-based antihypertensive therapy, an angiotensin converting enzyme-inhibitor-based antihypertensive therapy causes a greater regression of left ventricular hypertrophy. METHODS: Subjects were randomly assigned to either open-label lisinopril (n = 100) or atenolol (n = 100) each administered three times per week after dialysis. Monthly monitored home blood pressure (BP) was controlled to <140/90 mmHg with medications, dry weight adjustment and sodium restriction. The primary outcome was the change in left ventricular mass index (LVMI) from baseline to 12 months. RESULTS: At baseline, 44-h ambulatory BP was similar in the atenolol (151.5/87.1 mmHg) and lisinopril groups, and improved similarly over time in both groups. However, monthly measured home BP was consistently higher in the lisinopril group despite the need for both a greater number of antihypertensive agents and a greater reduction in dry weight. An independent data safety monitoring board recommended termination because of cardiovascular safety. Serious cardiovascular events in the atenolol group occurred in 16 subjects, who had 20 events, and in the lisinopril group in 28 subjects, who had 43 events {incidence rate ratio (IRR) 2.36 [95% confidence interval (95% CI) 1.36-4.23, P = 0.001]}. Combined serious adverse events of myocardial infarction, stroke and hospitalization for heart failure or cardiovascular death in the atenolol group occurred in 10 subjects, who had 11 events and in the lisinopril group in 17 subjects, who had 23 events (IRR 2.29, P = 0.021). Hospitalizations for heart failure were worse in the lisinopril group (IRR 3.13, P = 0.021). All-cause hospitalizations were higher in the lisinopril group [IRR 1.61 (95% CI 1.18-2.19, P = 0.002)]. LVMI improved with time; no difference between drugs was noted. CONCLUSIONS: Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During the last two decades, HBPM has been used increasingly in clinical hypertension research [17,155,267–273].”
In the citing paper
“During the last two decades, HBPM has been used increasingly in clinical hypertension research [17,155,267–273].”
Citations
Cites
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,226
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy
Cice, G., Ferrara, L., D’Andrea, A., D’Isa, S., Benedetto, A. D., Cittadini, A., Russo, P. E., Golino, P., & Calabrò, R. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00241-9 · Cited by 534
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519
Agarwal, R., Nissenson, A. R., BATLLE, D. C., Coyne, D. W., Trout, J. R., & Warnock, D. G. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00366-8 · Cited by 480
Self-citationHeerspink, H. J. L., Ninomiya, T., Zoungas, S., de Zeeuw, D., Grobbee, D. E., Jardine, M., Gallagher, M., Roberts, M. A., Cass, A., Neal, B. C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60212-9 · Cited by 433
Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP): A Randomized, Controlled Trial
Agarwal, R., Alborzi, P., Satyan, S., & Light, R. P. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.125674 · Cited by 349 · cited 1×
“An important cause of hypertension is volume excess but even after aggressive volume management, many patients receiving thrice-weekly dialysis remain hypertensive [4, 5].”
Self-citationZannad, F. M., Kessler, M., Lehert, P., Grünfeld, J., Thuilliez, C., Leizorovicz, A., Lechat, P. P., & for the Fosidial Investigators (2006) · Kidney International · doi:10.1038/sj.ki.5001657 · Cited by 333
Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population
Kalantar‐Zadeh, K., Kilpatrick, R. D., McAllister, C. J., Greenland, S., & Kopple, J. D. (2005) · Hypertension · doi:10.1161/01.hyp.0000154895.18269.67 · Cited by 226
Flagged first, then by citations
Cited by
Sorted by citations
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Gomes, M. A. M., Brandão, A. A., Feitosa, A. D. M., Machado, C. A., Poli‐de‐Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,389
Macdougall, I. C., Bircher, A. J., Eckardt, K., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiß, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 489
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 494
House, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P. V. J., Kasiske, B. L., Deswal, A. M., deFilippi, C. R., Cleland, J. G. F., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.022 · Cited by 481
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 445
Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P. A., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 399
Self-citationAtherosclerosis in Chronic Kidney Disease
Valdivielso, J. M., Rodrı́guez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortíz, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 325
The heart and vascular system in dialysis
Wanner, C., Amann, K., & Shoji, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30508-6 · Cited by 309
Flythe, J. E., Chang, T. I., Gallagher, M., Lindley, E. J., Madero, M., Sarafidis, P. A., Unruh, M. L., Wang, A. Y.-M., Weiner, D. E., Cheung, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.01.046 · Cited by 304
How Dangerous Is Hyperkalemia?
Montford, J. R., & Linas, S. L. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121344 · Cited by 251
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P. W., Ferro, C. J., Halimi, J., Heine, G. H., Jadoul, M. Y., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 242
Self-citationAssessment and Management of Hypertension in Patients on Dialysis
Agarwal, R., Flynn, J. T., Pogue, V. A., Rahman, M., Reisin, E., & Weir, M. R. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060601 · Cited by 194
Self-citationDialysis for Chronic Kidney Failure
Flythe, J. E., & Watnick, S. G. (2024) · JAMA · doi:10.1001/jama.2024.16338 · Cited by 220
Parati, G., Stergiou, G. S., Bilo, G., Kollias, A., Pengo, M., Ochoa, J. E., Agarwal, R., Asayama, K., Asmar, R., Burnier, M., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002922 · Cited by 178
Self-citationHemodialysis‐induced cardiovascular disease
Ahmadmehrabi, S., & Tang, W. H. W. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12694 · Cited by 191
Three Generations of β-blockers: History, Class Differences and Clinical Applicability
do Vale, G. T., Ceron, C. S., Gonzaga, N. A., Simplicio, J. A., & Padovan, J. C. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180918102735 · Cited by 172
Preservation of residual kidney function in hemodialysis patients: reviving an old concept
Mathew, A. T., Fishbane, S. N., Obi, Y., & Kalantar‐Zadeh, K. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.037 · Cited by 164
Evolving concepts in the pathogenesis of uraemic cardiomyopathy
Wang, X., & Shapiro, J. I. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0101-8 · Cited by 170
Sudden Cardiac Death Among Hemodialysis Patients
Makar, M. S., & Pun, P. H. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.006 · Cited by 151
Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
Sinha, A. D., & Agarwal, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04330418 · Cited by 133
Self-citationQuach, K., Lvtvyn, L., Baigent, C., Bueti, J., Garg, A. X., Hawley, C. M., Haynes, R., Manns, B., Perkovic, V., Rabbat, C. G., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.011 · Cited by 101
Global challenges posed by the growth of end-stage renal disease
Wetmore, J. B., & Collins, A. J. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0021-7 · Cited by 100
Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 111
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Gregg, L. P., & Hedayati, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.007 · Cited by 93
Future Avenues to Decrease Uremic Toxin Concentration
Vanholder, R. C., Eloot, S., & Glorieux, G. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.08.029 · Cited by 87
Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials
Thomopoulos, C., Bazoukis, G., Tsioufis, C. P., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002523 · Cited by 96
Hypertension in dialysis patients
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P. W., Ferro, C. J., Halimi, J., Heine, G. H., Jadoul, M. Y., Jarraya, F., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001283 · Cited by 85
Self-citationBansal, N., Artinian, N. T., Bakris, G. L., Chang, T. I., Cohen, J. B., Flythe, J. E., Lea, J. P., Vongpatanasin, W., & Chertow, G. M. (2023) · Hypertension · doi:10.1161/hyp.0000000000000230 · Cited by 101
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 92
Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis
Georgianos, P. I., & Agarwal, R. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.129 · Cited by 80
Self-citationLiu, Y., Ma, X., Zheng, J., Jia, J., & Yan, T. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0605-7 · Cited by 75
BP in Dialysis: Results of a Pilot Study
Miskulin, D. C., Gassman, J., Schrader, R., Gul, A., Jhamb, M., Ploth, D. W., Negrea, L. A., Kwong, R. Y. K., Levey, A. S., Singh, A. K., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020135 · Cited by 70
The Safety of Eplerenone in Hemodialysis Patients
Walsh, M. W., Manns, B., Garg, A. X., Bueti, J., Rabbat, C. G., Smyth, A., Tyrwhitt, J., Bosch, J., Gao, P., Devereaux, P. J., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12371214 · Cited by 67
The Interplay Between CKD, Sudden Cardiac Death, and Ventricular Arrhythmias
Pun, P. H. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.06.007 · Cited by 63
Intradialysis Hypertension in End-Stage Renal Disease Patients
Georgianos, P. I., Sarafidis, P. A., & Zoccali, C. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05858 · Cited by 68
Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use
Bakris, G. L., Burkart, J. M., Weinhandl, E. D., McCullough, P. A., & Kraus, M. A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.05.026 · Cited by 60
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 57
Assimon, M. M., Brookhart, M. A., Fine, J. P., HEISS, G. M., Layton, J. B., & Flythe, J. E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.02.350 · Cited by 54
Blood pressure targets for hemodialysis patients
Turner, J. M., & Peixoto, A. J. (2017) · Kidney International · doi:10.1016/j.kint.2017.01.038 · Cited by 53
Pharmacotherapy of Hypertension in Chronic Dialysis Patients
Georgianos, P. I., & Agarwal, R. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00870116 · Cited by 52
Self-citationSpecial situations: Intradialytic hypertension/chronic hypertension and intradialytic hypotension
Buren, P. N. V., & Inrig, J. K. (2017) · Seminars in Dialysis · doi:10.1111/sdi.12631 · Cited by 51
Alkhatib, L., Díaz, L. A. V., Varma, S., Chowdhary, A., Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, S. A., & Kalra, K. (2023) · Cureus · doi:10.7759/cureus.34572 · Cited by 51
Roberts, M. A., Pilmore, H., Ierino, F. L., Badve, S. V., Cass, A., Garg, A. X., Isbel, N. M., Krum, H., Pascoe, E. M., Perkovic, V., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.029 · Cited by 46
Molecular regulation of the renin–angiotensin system in haemodialysis patients
Kovarik, J. J., Antlanger, M., Domenig, O., Kaltenecker, C. C., Hecking, M., Haidinger, M., Werzowa, J. M., Kopecky, C., & Säemann, M. D. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu265 · Cited by 41
Sternlicht, H., & Bakris, G. L. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.001 · Cited by 40
Diagnosis and treatment of hypertension in dialysis patients: a systematic review
Kim, I. S., Kim, S., Yoo, T., & Kim, J.-K. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00240-x · Cited by 52
Karaboyas, A., Xu, H., Morgenstern, H., Locatelli, F., Jadoul, M. Y., Nitta, K., Dasgupta, I., Tentori, F., Port, F. K., & Robinson, B. M. (2018) · Kidney International · doi:10.1016/j.kint.2018.03.013 · Cited by 36
Sudden cardiac death in CKD patients
Franczyk, B., Gluba-Brzózka, A., Wranicz, J. K., Banach, M., Olszewski, R., & Rysz, J. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0994-0 · Cited by 34
Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management
Georgianos, P. I., & Agarwal, R. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000315 · Cited by 34
Self-citationSudden cardiac death in haemodialysis patients: Preventative options
Chiu, D. Y. Y., Sinha, S., Kalra, P. A., & Green, D. (2014) · Nephrology · doi:10.1111/nep.12337 · Cited by 32
Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors
Chang, T. I. (2017) · Seminars in Dialysis · doi:10.1111/sdi.12633 · Cited by 32
Antihypertensive Medications in End‐Stage Renal Disease
Denker, M. G., & Cohen, D. L. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12369 · Cited by 35
Cardiovascular Disease in Dialysis Patients
Jegatheesan, D., Yang, W.-L., Krishnasamy, R., Hawley, C., & Johnson, D. (2017) · InTech eBooks · doi:10.5772/intechopen.70362
Ott, C., Schmid, A., Ditting, T., Veelken, R. A., Uder, M., & Schmieder, R. E. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01697-7 · Cited by 30
Interventions for fatigue in people with kidney failure requiring dialysis
Natale, P., Ju, A., Strippoli, G. F., Craig, J. C., Saglimbene, V. M., Unruh, M. L., Stallone, G., & Jauré, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013074.pub2 · Cited by 31
Beta blockers in patients with end‐stage renal disease—Evidence‐based recommendations
Weir, M. A., & Herzog, C. A. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12691 · Cited by 29
Shen, J. I., Saxena, A. B., Montez‐Rath, M. E., Chang, T. I., & Winkelmayer, W. C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw053 · Cited by 28
Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain
Miskulin, D. C., & Weiner, D. E. (2017) · Seminars in dialysis · doi:10.1111/sdi.12586 · Cited by 26
The cardiovascular–dialysis nexus: the transition to dialysis is a treacherous time for the heart
Chan, K. T. K., Moe, S. M., Saran, R., & Libby, P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1049 · Cited by 32
Pro: Ambulatory blood pressure should be used in all patients on hemodialysis
Agarwal, R. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv243 · Cited by 27
Self-citationEffect of Lisinopril and Atenolol on Aortic Stiffness in Patients on Hemodialysis
Georgianos, P. I., & Agarwal, R. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09981014 · Cited by 27
Self-citationSanidas, E. A., Böhm, M., Oikonomopoulou, I., Dinopoulou, P., Papadopoulos, D. P., Michalopoulou, H., Tsioufis, K. P., Mancia, G., & Thomopoulos, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf291 · Cited by 26
Bansal, N., Glidden, D. V., Mehrotra, R., Townsend, R. R., Cohen, J. B., Linke, L., Palad, F., Larson, H., & Hsu, C. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.06.014 · Cited by 26
Jin, J., Guo, X., & Yu, Q. (2019) · Blood Purification · doi:10.1159/000496083 · Cited by 26
Wu, P., Lin, Y., Liu, J., Tsai, Y., Kuo, M., Chiu, Y., Hwang, S., & Carrero, J. J. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa248 · Cited by 25
Georgianos, P., & Agarwal, R. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.01.018 · Cited by 22
Self-citationWhat Happens to the Heart in Chronic Kidney Disease?
Rutherford, E., & Mark, P. B. (2017) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2017.117 · Cited by 24
Blood pressure control in conventional hemodialysis
Georgianos, P. I., & Agarwal, R. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12741 · Cited by 24
Self-citationβ-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review
Tella, A., Vang, W., Ikeri, E. C., Taylor, O., Zhang, A., Mazanec, M., Raju, S. I., & Ishani, A. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100460 · Cited by 20
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis
Zhou, H. C., Sim, J. J., Shi, J. M., Shaw, S. F., Lee, M. S., Neyer, J. R., Kovesdy, C. P., Kalantar‐Zadeh, K., & Jacobsen, S. J. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.07.023 · Cited by 21
Baroreflex activation therapy in patients with end-stage renal failure
Beige, J., Koziolek, M. J., Hennig, G., Hamza, A., Wendt, R. T., Muller, G. A., & Wallbach, M. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000697 · Cited by 18
Loutradis, C., Bikos, A., Raptis, V., Afkou, Z., Tzanis, G. S., Pyrgidis, N., Panagoutsos, S. A., Pasadakis, P. S., Balaskas, E. V., Zebekakis, P. E., et al. (2019) · Hypertension Research · doi:10.1038/s41440-018-0194-2 · Cited by 18
Personalizing heart failure management in chronic kidney disease patients
Banerjee, D., & Wang, A. Y.-M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab026 · Cited by 19
Management of acute intradialytic cardiovascular complications: Updated overview (Review)
Timofte, D., Tănăsescu, M., Balan, D., Tulin, A., Știru, O., Vacaroiu, I., Mihai, A., Popa, C., Cosconel, C.-I., Enyedi, M., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9713 · Cited by 15
Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis Mortality
Gosmanova, E. O., Molnar, M. Z., Naseer, A., Sumida, K., Potukuchi, P. K., Gaipov, A., Wall, B. M., Thomas, F., Streja, E., Kalantar‐Zadeh, K., et al. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.037 · Cited by 17
Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease
Jablonski, K., & Chonchol, M. (2014) · F1000Prime Reports · doi:10.12703/p6-72 · Cited by 17
Kim, E. D., Sozio, S. M., Estrella, M. M., Jaar, B. G., Shafi, T., Meoni, L. A., Kao, W. H. L., Lima, J. A. C., & Parekh, R. S. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0131-4 · Cited by 16
Left ventricular geometric patterns in end‐stage kidney disease: Determinants and course over time
Nubé, M. J., Hoekstra, T., Doganer, V., Bots, M. L., Blankestijn, P. J., van den Dorpel, M., Otto Kamp, B., ter Wee, P. M., van Zuijdewijn, C. L. M. D. R., & Grooteman, M. P. C. (2018) · Hemodialysis International · doi:10.1111/hdi.12644 · Cited by 16
Vaios, V., Georgianos, P. I., Vareta, G., Dounousi, E. C., Dimitriadis, C., Eleftheriadis, T., Papagianni, A. A., Zebekakis, P. E., & Liakopoulos, V. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13443 · Cited by 17
ACE inhibitors and the risk of fractures: a meta-analysis of observational studies
Cheng, Y., Huang, Z.-Z., Shen, Z., Wu, H., Peng, J., Waye, M. M. Y., Rao, S., & Yang, L. (2016) · Endocrine · doi:10.1007/s12020-016-1201-5 · Cited by 16
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis
Ruggenenti, P. L., Podestà, M. A., Trillini, M., Perna, A., Peracchi, T., Rubis, N., Villa, D., Martinetti, D., Cortinovis, M., Ondei, P., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12940820 · Cited by 15
Jardine, A. G. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv244 · Cited by 16
Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?
Zoccali, C., & Mallamaci, F. (2014) · Kidney International · doi:10.1038/ki.2014.155 · Cited by 15
Blood pressure in hemodialysis
Georgianos, P. I., & Agarwal, R. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000359 · Cited by 15
Self-citationÖsterreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 15
Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients
Shafi, T., Sozio, S. M., Luly, J. R., Bandeen‐Roche, K., Peter, W. L. S., Ephraim, P. L., McDermott, A., Herzog, C. A., Crews, D. C., Scialla, J. J., et al. (2017) · Medicine · doi:10.1097/md.0000000000005924 · Cited by 14
Georgianos, P. I., & Agarwal, R. (2019) · Seminars in Dialysis · doi:10.1111/sdi.12837 · Cited by 14
Self-citationNew insights into cardiovascular risk factors and outcomes
Sarafidis, P. A., & Bakris, G. L. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.242 · Cited by 14
Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis
Buren, P. N. V. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0805-y · Cited by 14
Bikos, A., Loutradis, C., Angeloudi, E., Καρπέτας, Α., Raptis, V., Kalaitzidis, R., Panagoutsos, S. A., Pasadakis, P. S., Balaskas, I., Liakopoulos, V., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001891 · Cited by 14
Association between higher rates of cardioprotective drug use and survival in patients on dialysis
Tang, Y., Brooks, J. M., Wetmore, J. B., & Shireman, T. I. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.12.007 · Cited by 13
Shaman, A. M., Smyth, B. J., Arnott, C. G., Palmer, S. C., Mihailidou, A. S., Jardine, M., Gallagher, M., Perkovic, V., & Jun, M. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12201019 · Cited by 13
Liu, Y., Zheng, Y., Wang, L., Zhong, X., Qin, D., Chen, W., Tan, R., & Liu, Y. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02385-4 · Cited by 12
β-blockers in hemodialysis: simple questions, complicated answers
Hundemer, G. L., Sood, M. M., & Canney, M. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa249 · Cited by 13
Hui, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_6 · Cited by 13
β-Blockers in Dialysis Patients
Shroff, G. R., & Herzog, C. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080831 · Cited by 12
Borzych-Dużałka, D., Shroff, R., Ranchin, B., Zhai, Y., Paglialonga, F., Kari, J., Ahn, Y., Awad, H. S., Loza, R., Hooman, N., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.03.016 · Cited by 12
Hypertension Management in Transition: From CKD to ESRD
Valika, A. K., & Peixoto, A. J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.02.002 · Cited by 11
Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis
Maruyama, T., Takashima, H., & Abe, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746272 · Cited by 11
Uncertainties in BP management in dialysis patients
Doulton, T. W. R., Swift, P. A., Murtaza, A., & Dasgupta, I. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12880 · Cited by 12
Metadata
- Authors
- Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., & Tegegne, G. G.
- Affiliations
- Richard L. Roudebush VA Medical Center (US)
- Corresponding author
- Agarwal, Rajiv
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 29
- Issue
- 3
- Pages
- 672-681
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC3938300
- OpenAlex
- W2162199393
- Cited by
- 232
- References
- 22
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 14 · 2023: 19 · 2022: 15 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 19 · 2017: 19 · 2016: 24 · 2015: 24 · 2014: 17
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, other-oa)
- Purdue University Indianapolis (Indiana University) (submittedVersion, other-oa)
- Publisher
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (2R01-DK063020-10)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- hypertension, hemodialysis, lisinopril, atenolol, left ventricular hypertrophy, left ventricular mass index, antihypertensive therapy, ACE inhibitors, beta-blockers, cardiovascular events, heart failure hospitalization, dry weight adjustment, sodium restriction, end-stage renal disease, ambulatory blood pressure monitoring, cardiovascular safety, trial termination
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Atenolol, Double-Blind Method, Female, Renal Dialysis, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Myocardial Infarction, Treatment Failure, Hypertrophy, Left Ventricular, Lisinopril, Early Termination of Clinical Trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
